Sustainability Focus Medicines for Europe represents a broad ecosystem of generic, biosimilar and value-added medicines across Europe with a strong emphasis on sustainable access to high quality medicines, investment in R&D, and partnerships to support sustainable healthcare systems.

R&D Investment Member companies invest up to 17% of turnover in R&D, indicating substantial ongoing innovation potential and opportunities to collaborate on biosimilars, new value-added formulations, and advanced manufacturing processes.

Regulatory Advocacy The group actively engages in regulatory modernization initiatives, such as promoting electronic Product Information, which creates pathways for faster market access, digital documentation, and potential collaboration with regulatory tech providers.

Industry Networking Active participation in high-profile conferences and legal affairs discussions signals strong influence and access to decision-makers across Europe, offering opportunities for partnership, policy alignment services, and thought leadership engagements.

Market Positioning With a focus on increasing access to affordable medicines and expanding biosimilars and value-added options, there is potential to explore supply chain optimization, competitive pricing analytics, and hospital-focused solutions for efficiency and patient outcomes.